adenine has been researched along with Liver Failure in 24 studies
Liver Failure: Severe inability of the LIVER to perform its normal metabolic functions, as evidenced by severe JAUNDICE and abnormal serum levels of AMMONIA; BILIRUBIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; LACTATE DEHYDROGENASES; and albumin/globulin ratio. (Blakiston's Gould Medical Dictionary, 4th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "A randomized, open-label comparative study of entecavir versus adefovir therapy was performed in subjects with chronic hepatitis B who had hepatic decompensation (Child-Turcotte-Pugh score ≥7)." | 9.15 | Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. ( Beebe, S; Bialkowska, J; Brown, RS; Cheinquer, H; Cooney, E; Jeffers, L; Leung, N; Liaw, YF; Myers, RP; Peng, CY; Raptopoulou-Gigi, M; Sarin, SK; Tang, S; Tanwandee, T; Tsai, N, 2011) |
| "Lamivudine treatment in patients with chronic hepatitis B virus (HBV) infection may improve clinical state and suppress viral replication before liver transplantation." | 9.11 | Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. ( Chan, SC; Fan, ST; Lau, GK; Liu, CL; Lo, CM; Ng, IO, 2005) |
| "The aims of this study were to select the patients with a potential for progression to hepatic failure due to lamivudine-resistant HBV and to standardize the treatment for patients with lamivudine-resistant HBV." | 7.74 | Predictive factors associated with the progression to hepatic failure caused by lamivudine-resistant HBV. ( Hino, T; Hisamochi, A; Ide, T; Koga, H; Koga, Y; Kumashiro, R; Kuwahara, R; Ogata, K; Sata, M; Takao, Y; Tanaka, K, 2008) |
| "We determined the clinical outcome of hepatitis e antigen (HBeAg)-negative chronic hepatitis B patients treated with long-term nucleos(t)ide analog therapy starting with lamivudine." | 7.73 | Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. ( Dimakopoulos, K; Dimou, E; Hadziyannis, SJ; Kitis, G; Manesis, E; Manolakopoulos, S; Papatheodoridis, GV; Rapti, I; Tzourmakliotis, D, 2005) |
| "The susceptibility of adefovir-resistant hepatitis B virus (HBV) mutants is only reduced by 3-10-fold in in vitro studies, suggesting that virologic breakthrough and clinical deterioration are unlikely." | 7.73 | Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. ( Andreone, P; Cursaro, C; Fung, SK; Han, SH; Hussain, M; Keeffe, EB; Lok, AS; Marrero, JA; Rajender Reddy, K; Regev, A; Richtmyer, P, 2005) |
| "Lamivudine is a treatment option for the therapy of chronic hepatitis B with an excellent safety profile." | 7.72 | Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated. ( Flemming, P; Klempnauer, J; Manns, MP; Nashan, B; Niemann, P; Rohde, P; Tillmann, HL; Tischendorf, JJ; Trautwein, C; Wiegand, J, 2004) |
| " Hepatitis B immunoglobulin and adefovir dipivoxil were initiated." | 7.70 | Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin. ( Gibbs, CS; Howard, T; Jacobsmeyer, S; Lamy, P; Murray, A; Peters, MG; Singer, G; Xiong, X, 1999) |
| "In patients with hepatitis B-related HCC, adefovir antiviral therapy reduced late HCC recurrence and significantly improved overall survival after R0 hepatic resection." | 5.20 | Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial. ( Huang, G; Lau, WY; Pan, ZY; Shen, F; Wang, ZG; Wu, MC; Yuan, SX; Zhou, WP, 2015) |
| "A randomized, open-label comparative study of entecavir versus adefovir therapy was performed in subjects with chronic hepatitis B who had hepatic decompensation (Child-Turcotte-Pugh score ≥7)." | 5.15 | Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. ( Beebe, S; Bialkowska, J; Brown, RS; Cheinquer, H; Cooney, E; Jeffers, L; Leung, N; Liaw, YF; Myers, RP; Peng, CY; Raptopoulou-Gigi, M; Sarin, SK; Tang, S; Tanwandee, T; Tsai, N, 2011) |
| "Lamivudine treatment in patients with chronic hepatitis B virus (HBV) infection may improve clinical state and suppress viral replication before liver transplantation." | 5.11 | Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. ( Chan, SC; Fan, ST; Lau, GK; Liu, CL; Lo, CM; Ng, IO, 2005) |
| "The aims of this study were to select the patients with a potential for progression to hepatic failure due to lamivudine-resistant HBV and to standardize the treatment for patients with lamivudine-resistant HBV." | 3.74 | Predictive factors associated with the progression to hepatic failure caused by lamivudine-resistant HBV. ( Hino, T; Hisamochi, A; Ide, T; Koga, H; Koga, Y; Kumashiro, R; Kuwahara, R; Ogata, K; Sata, M; Takao, Y; Tanaka, K, 2008) |
| "We determined the clinical outcome of hepatitis e antigen (HBeAg)-negative chronic hepatitis B patients treated with long-term nucleos(t)ide analog therapy starting with lamivudine." | 3.73 | Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. ( Dimakopoulos, K; Dimou, E; Hadziyannis, SJ; Kitis, G; Manesis, E; Manolakopoulos, S; Papatheodoridis, GV; Rapti, I; Tzourmakliotis, D, 2005) |
| "The susceptibility of adefovir-resistant hepatitis B virus (HBV) mutants is only reduced by 3-10-fold in in vitro studies, suggesting that virologic breakthrough and clinical deterioration are unlikely." | 3.73 | Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. ( Andreone, P; Cursaro, C; Fung, SK; Han, SH; Hussain, M; Keeffe, EB; Lok, AS; Marrero, JA; Rajender Reddy, K; Regev, A; Richtmyer, P, 2005) |
| "3%) patients developed hepatitis B virus DNA breakthrough 47 and 53 months, respectively, after transplantation, but they remained well after treatment with adefovir." | 3.72 | Live-donor liver transplantation for acute-on-chronic hepatitis B liver failure. ( Fan, ST; Lai, CL; Liu, CL; Lo, CM; Wei, WI; Wong, J; Yong, BH, 2003) |
| "Lamivudine is a treatment option for the therapy of chronic hepatitis B with an excellent safety profile." | 3.72 | Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated. ( Flemming, P; Klempnauer, J; Manns, MP; Nashan, B; Niemann, P; Rohde, P; Tillmann, HL; Tischendorf, JJ; Trautwein, C; Wiegand, J, 2004) |
| "Hepatitis B virus (HBV) recurrence following liver transplantation (LTx) has been controllable primarily with the use of hepatitis B immune globulin (HBIg) and lamivudine (LAM)." | 3.72 | Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade. ( De Medina, M; Madariaga, J; Montalbano, M; Neff, GW; Nery, C; Nery, J; O'brien, CB; Ruiz, P; Safdar, K; Schiff, ER; Shire, N; Tzakis, AG, 2004) |
| " Hepatitis B immunoglobulin and adefovir dipivoxil were initiated." | 3.70 | Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin. ( Gibbs, CS; Howard, T; Jacobsmeyer, S; Lamy, P; Murray, A; Peters, MG; Singer, G; Xiong, X, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.17) | 18.2507 |
| 2000's | 12 (50.00) | 29.6817 |
| 2010's | 10 (41.67) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Malek, AE | 1 |
| Nieto, Y | 1 |
| Szvalb, AD | 1 |
| Siddiqui, S | 1 |
| Shafi, MA | 1 |
| Hwang, JP | 1 |
| Raad, II | 1 |
| Torres, HA | 1 |
| Price, J | 1 |
| Rao, W | 1 |
| Xie, M | 1 |
| Shen, Z | 1 |
| Huang, G | 1 |
| Lau, WY | 1 |
| Wang, ZG | 1 |
| Pan, ZY | 1 |
| Yuan, SX | 1 |
| Shen, F | 1 |
| Zhou, WP | 1 |
| Wu, MC | 1 |
| Jiao, M | 1 |
| Ren, F | 1 |
| Zhou, L | 1 |
| Zhang, X | 2 |
| Zhang, L | 1 |
| Wen, T | 1 |
| Wei, L | 1 |
| Wang, X | 1 |
| Shi, H | 1 |
| Bai, L | 1 |
| Zheng, S | 1 |
| Zhang, J | 1 |
| Chen, Y | 1 |
| Han, Y | 1 |
| Zhao, C | 1 |
| Duan, Z | 1 |
| Kim, SK | 1 |
| Kim, SR | 1 |
| Imoto, S | 1 |
| Tohyama, M | 1 |
| Otono, Y | 1 |
| Tamura, T | 1 |
| Kuwahara, R | 2 |
| Kumashiro, R | 2 |
| Ide, T | 2 |
| Koga, Y | 2 |
| Hino, T | 2 |
| Hisamochi, A | 1 |
| Tanaka, K | 1 |
| Ogata, K | 1 |
| Koga, H | 1 |
| Takao, Y | 1 |
| Sata, M | 2 |
| Muñoz Bertrán, E | 1 |
| Pérez Ceballos, E | 1 |
| Gómez Espín, R | 1 |
| Ortega González, I | 1 |
| Liaw, YF | 1 |
| Raptopoulou-Gigi, M | 1 |
| Cheinquer, H | 1 |
| Sarin, SK | 1 |
| Tanwandee, T | 1 |
| Leung, N | 1 |
| Peng, CY | 1 |
| Myers, RP | 1 |
| Brown, RS | 1 |
| Jeffers, L | 1 |
| Tsai, N | 1 |
| Bialkowska, J | 1 |
| Tang, S | 1 |
| Beebe, S | 1 |
| Cooney, E | 1 |
| Kohler, JJ | 1 |
| Hosseini, SH | 1 |
| Cholongitas, E | 1 |
| Papatheodoridis, GV | 2 |
| Qayyum, S | 1 |
| Dong, H | 1 |
| Kovacic, D | 1 |
| Sohail, S | 1 |
| Waters, B | 1 |
| Thornton, C | 1 |
| Corbett, CE | 1 |
| Liu, CL | 2 |
| Fan, ST | 2 |
| Lo, CM | 2 |
| Wei, WI | 1 |
| Yong, BH | 1 |
| Lai, CL | 1 |
| Wong, J | 1 |
| Wiegand, J | 1 |
| Tischendorf, JJ | 1 |
| Nashan, B | 1 |
| Klempnauer, J | 1 |
| Flemming, P | 1 |
| Niemann, P | 1 |
| Rohde, P | 1 |
| Manns, MP | 1 |
| Trautwein, C | 1 |
| Tillmann, HL | 1 |
| Inoue, H | 1 |
| Tanabe, R | 1 |
| Tanaka, E | 1 |
| Hatano, E | 1 |
| Tanaka, A | 1 |
| Kanazawa, A | 1 |
| Tsuyuki, S | 1 |
| Tsunekawa, S | 1 |
| Iwata, S | 1 |
| Takahashi, R | 1 |
| Chance, B | 1 |
| Yamaoka, Y | 1 |
| Neff, GW | 1 |
| O'brien, CB | 1 |
| Nery, J | 1 |
| Shire, N | 1 |
| Montalbano, M | 1 |
| Ruiz, P | 1 |
| Nery, C | 1 |
| Safdar, K | 1 |
| De Medina, M | 1 |
| Tzakis, AG | 1 |
| Schiff, ER | 1 |
| Madariaga, J | 1 |
| Dimou, E | 1 |
| Dimakopoulos, K | 1 |
| Manolakopoulos, S | 1 |
| Rapti, I | 1 |
| Kitis, G | 1 |
| Tzourmakliotis, D | 1 |
| Manesis, E | 1 |
| Hadziyannis, SJ | 1 |
| Lau, GK | 1 |
| Chan, SC | 1 |
| Ng, IO | 1 |
| Fung, SK | 1 |
| Andreone, P | 1 |
| Han, SH | 1 |
| Rajender Reddy, K | 1 |
| Regev, A | 1 |
| Keeffe, EB | 1 |
| Hussain, M | 1 |
| Cursaro, C | 1 |
| Richtmyer, P | 1 |
| Marrero, JA | 1 |
| Lok, AS | 1 |
| Masiá, M | 1 |
| Gutiérrez, F | 1 |
| Padilla, S | 1 |
| Ramos, JM | 1 |
| Pascual, J | 1 |
| Bruno, R | 1 |
| Sacchi, P | 1 |
| Filice, G | 1 |
| Matthews, GV | 1 |
| Cooper, DA | 1 |
| Dore, GJ | 1 |
| Peters, MG | 1 |
| Singer, G | 1 |
| Howard, T | 1 |
| Jacobsmeyer, S | 1 |
| Xiong, X | 1 |
| Gibbs, CS | 1 |
| Lamy, P | 1 |
| Murray, A | 1 |
4 reviews available for adenine and Liver Failure
| Article | Year |
|---|---|
An update on hepatitis B, D, and E viruses.
Topics: Adenine; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Hepatitis D, Chronic; Hepatitis E | 2014 |
[Hepatitis B reactivation in an HbsAg-negative/anti-HBc-positive patient with B-cell non-Hodgkin lymphoma receiving chemotherapy with rituximab].
Topics: Adenine; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody | 2010 |
High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review.
Topics: Adenine; Antiviral Agents; DNA, Viral; Guanine; Hepatitis B; Hepatitis B virus; Humans; Immunoglobul | 2013 |
Severe toxicity associated with the combination of tenofovir and didanosine: case report and review.
Topics: Acidosis, Lactic; Acute Disease; Adenine; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Fe | 2005 |
3 trials available for adenine and Liver Failure
| Article | Year |
|---|---|
Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Hepatitis | 2015 |
Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study.
Topics: Adenine; Antiviral Agents; DNA, Viral; Dose-Response Relationship, Drug; Drug Resistance, Viral; Fem | 2011 |
Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA-Directed DNA Polymerase; DNA, Viral; Drug Resistance, Vi | 2005 |
17 other studies available for adenine and Liver Failure
| Article | Year |
|---|---|
Hepatitis B Virus-associated Liver Failure in a Patient With B-cell Non-Hodgkin Lymphoma After Anti-cancer Therapy Including Ibrutinib.
Topics: Adenine; Aged; Aged, 80 and over; Hepatitis B virus; Humans; Liver Failure; Lymphoma, Non-Hodgkin; M | 2020 |
Tenofovir disoproxil fumarate rescue therapy for HBV recurrence in two liver transplant recipients with previous multiple nucleo(s/t)ide treatment failures.
Topics: Adenine; Aged; Follow-Up Studies; Graft Rejection; Graft Survival; Hepatitis B; Humans; Liver Failur | 2014 |
Peroxisome proliferator-activated receptor α activation attenuates the inflammatory response to protect the liver from acute failure by promoting the autophagy pathway.
Topics: Acute Disease; Adenine; Adult; Animals; Autophagy; Autophagy-Related Protein 7; Cells, Cultured; Che | 2014 |
Rhabdomyolysis due to lamivudine re-administration in a patient with HBV-related hepatic failure caused by interruption of lamivudine and adefovir.
Topics: Adenine; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis B, Chr | 2015 |
Predictive factors associated with the progression to hepatic failure caused by lamivudine-resistant HBV.
Topics: Adenine; Adult; Antiviral Agents; Bilirubin; Disease Progression; Drug Resistance, Viral; Female; Fo | 2008 |
Subcellular renal proximal tubular mitochondrial toxicity with tenofovir treatment.
Topics: Adenine; Animals; Cardiomyopathies; Cell Separation; DNA, Mitochondrial; Female; HIV Infections; HIV | 2011 |
Combination therapy efavirenz/emtricitabine/tenofovir disoproxil fumarate associated with hepatic failure.
Topics: Adenine; Adult; Deoxycytidine; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fum | 2012 |
Live-donor liver transplantation for acute-on-chronic hepatitis B liver failure.
Topics: Acute Disease; Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Follow-Up Studies; Graft Surviv | 2003 |
Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Genotype; Hep | 2004 |
Adefovir dipivoxil as a treatment for hepatic failure caused by lamivudine-resistant HBV strains.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance; Hepatitis B; Hepatitis B virus; Humans; Lami | 2004 |
Inhibition of tumor necrosis factor-induced apoptosis in transgenic mouse liver expressing creatine kinase.
Topics: Adenine; Adenosine Diphosphate; Adenosine Triphosphate; Animals; Caspase 3; Caspases; Creatine Kinas | 2004 |
Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Graft Survival; Hepatitis B; | 2004 |
Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepatitis B e | 2005 |
Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation.
Topics: Adenine; Adult; Aged; Antiviral Agents; Disease Progression; Drug Resistance, Viral; Hepatitis B; He | 2005 |
Could tenofovir modify the model end-stage liver disease (MELD) score in patients with end-stage liver disease eligible for liver transplantation?
Topics: Adenine; Anti-HIV Agents; Humans; Liver Failure; Liver Transplantation; Organophosphonates; Severity | 2007 |
Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir.
Topics: Adenine; CD4 Lymphocyte Count; DNA, Viral; Follow-Up Studies; Hepatitis B; Hepatitis B e Antigens; H | 2007 |
Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin.
Topics: Adenine; Adult; Antiviral Agents; Carrier State; DNA-Directed DNA Polymerase; Drug Resistance; Femal | 1999 |